Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis

NCT ID: NCT01617057

Last Updated: 2017-11-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2017-07-31

Brief Summary

The aim of this study is to assess the efficacy of a biphosphonate (tiludronic acid, Skelid®, Sanofi-Aventis) in the treatment of inner ear involvement in advanced otosclerosis

Detailed Description

Otosclerosis is a bone dystrophy localized to middle and inner ears with unknown etiology. It principally concerns adult patients between 30 and 50 years of age. Women present with this disease 2 times more frequently than men. Family cases are observed in 50% with a dominant autosomal transmission and low penetrance (40%). In its early stages, the disease is mainly located at the stapediovestibular joint leading to its ankylosis and a conductive hearing loss. In its advanced stages, the lesions extend around the cochlea and vestibule, induce a sensorineural hearing loss which can progress to severe and profound deafness, and prolonged balance disorders. On CT-scan, disease foci show a demineralization. Their density is inversely correlated to the hearing loss. In early stage, hearing function is currently rehabilitated by conventional hearing aids or surgery. In advanced forms, cochlear involvement is not accessible to surgery, and rehabilitation is insured by he hearing aids or cochlear implants. Vestibular dysfunction is dealt with by physiotherapy or symptomatic treatment. Drugs with anabolic activity in bone, such as sodium fluoride and etidronate (first generation bisphosphonate, Didronel ®), appear to reduce the hearing loss and to increase the radiological density of disease foci. However, their efficacy is low and poorly documented. Their effect on vestibular function is unknown.

Moreover, ototoxicity has been reported for etidronate. New biphosphonates such as tiludronic acid (Skelid ®) have a significantly more potent inhibition of bone resorption and do not have an ototoxic effect. They have been used for the treatment or the prevention of postmenopausal osteoporosis and in Paget's disease with mild to moderate adverse effects in the majority of cases.

Conditions

Otosclerosis

Keywords

otosclerosis; inner ear; tiludronic acid

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Skelid

tiludronic acid

Group Type: EXPERIMENTAL

tiludronic acid

Intervention Type: DRUG

400 mg / day for 3 months

Control

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

400 mg / day for 3 month

Interventions

tiludronic acid

400 mg / day for 3 months

Intervention Type: DRUG

Placebo

400 mg / day for 3 month

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age between 18 and 75 years
• French citizen
• Signed consent for participation
• No dental infection
• No programmed dental surgery during the treatment
• Effective contraception for women of childbearing potential
• Patient with advanced otosclerosis defined by:
• Slowly progressive uni or bilateral hearing loss
• No past medical history of chronic otitis media
• No past medical history of other causes of cochlear damage (significant surgical trauma with a 30 dB deterioration of bone conduction at 4000 Hz in postoperative period, sound trauma, barotrauma, ototoxic drugs)
• Normal tympanic membranes
• A conductive or mixed hearing loss
• A moderate to severe hearing loss on at least one ear (average of thresholds at 500, 1000, 2000 and 4000 Hz) on air conduction between 30 and 90 dB.
• Normal tympanometry or with a decreased peak
• Absent ipsilateral stapedial reflex
• As possible, intraoperative confirmation of stapediovestibular ankylosis
• radiological confirmation if CT-scan before inclusion available

Exclusion Criteria

• Individuals not covered by the french public health insurance
• Pure-tone average < 30 dB ou > 90 dB
• Programmed stapes surgery during the observation period
• Previous treatment by biphosphonate
• Known intolerance to tiludronate
• Other contraindications to tiludronate treatment:
• allergy to biphosphonates
• hypersensitivity to one of the excipients
• severe renal failure (creatinine clearance < 30 mL/min)
• juvenile Paget's disease
• pregnancy and breastfeeding
• galactose intolerance, lactase insufficiency, glucose-galactose malabsorption
• Ongoing chemotherapy or radiotherapy or patient achieves of a cancer
• Long-term systemic steroid treatment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexis BOZORG-GRAYELI, Pr

Role: PRINCIPAL_INVESTIGATOR

Hôpital Général, CHU de Dijon

Locations

Beaujon Hospital

Paris, , France

Countries

France

Other Identifiers

P081235

Identifier Type: -

Identifier Source: org_study_id